Fellowship · San Antonio, TX
Sponsored by University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
The New England journal of medicine · 2024 · 761 citations · Eric Lawitz
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
The New England journal of medicine · 2024 · 417 citations · Eric Lawitz
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2021 · 829 citations · Prabhleen Chahal
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
The lancet. Gastroenterology & hepatology · 2023 · 457 citations · Eric Lawitz
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
The New England journal of medicine · 2024 · 257 citations · Eric Lawitz
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Journal of hepatology · 2023 · 185 citations · Eric Lawitz
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 191 citations · Prabhleen Chahal
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.
Nature medicine · 2023 · 156 citations · Eric Lawitz